150 related articles for article (PubMed ID: 33506682)
1. Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles.
Phung CD; Tran TH; Choi JY; Jeong JH; Ku SK; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2021 Feb; 13(5):5999-6010. PubMed ID: 33506682
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
3. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.
Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J
ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870
[TBL] [Abstract][Full Text] [Related]
5. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
6. Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.
Lu F; Hou L; Wang S; Yu Y; Zhang Y; Sun L; Wang C; Ma Z; Yang F
Drug Deliv; 2021 Dec; 28(1):963-972. PubMed ID: 34036867
[TBL] [Abstract][Full Text] [Related]
7. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract][Full Text] [Related]
8. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
9. Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC.
Chen L; Wang S; Liu Q; Zhang Z; Lin S; Zheng Q; Cheng M; Li Y; Cheng C
Colloids Surf B Biointerfaces; 2020 Sep; 193():111105. PubMed ID: 32417465
[TBL] [Abstract][Full Text] [Related]
10. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic multifunctional biodegradable polymers for pH- and ROS-responsive anticancer drug delivery.
Su M; Xiao S; Shu M; Lu Y; Zeng Q; Xie J; Jiang Z; Liu J
Colloids Surf B Biointerfaces; 2020 Sep; 193():111067. PubMed ID: 32388121
[TBL] [Abstract][Full Text] [Related]
12. A pH-Responsive Detachable PEG Shielding Strategy for Gene Delivery System in Cancer Therapy.
Guan X; Guo Z; Wang T; Lin L; Chen J; Tian H; Chen X
Biomacromolecules; 2017 Apr; 18(4):1342-1349. PubMed ID: 28272873
[TBL] [Abstract][Full Text] [Related]
13. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
14. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles.
Kim MG; Jo SD; Yhee JY; Lee BS; Lee SJ; Park SG; Kang SW; Kim SH; Jeong JH
Biochem Biophys Res Commun; 2017 Jul; 489(1):35-41. PubMed ID: 28533089
[TBL] [Abstract][Full Text] [Related]
17. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
18. pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells.
Yang Z; Sun N; Cheng R; Zhao C; Liu Z; Li X; Liu J; Tian Z
Biomaterials; 2017 Dec; 147():53-67. PubMed ID: 28930649
[TBL] [Abstract][Full Text] [Related]
19. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]